Oushvaa exists because the healthcare data layer was built sideways. Drug data, device data, and biologics data live in separate companies, separate schemas, separate trust boundaries. We're rebuilding it on one canonical layer.
Most healthcare data platforms were built one product at a time. Drug pipeline tools, device safety databases, biologics trackers — each started as a single-category company and acquired or partnered their way into adjacent categories when the market demanded cross-product intelligence. The result is a layer cake of incompatible schemas, lossy joins, and translation tables. A hospital procurement officer who wants to know "everything Cipla makes — drugs, devices, biosimilars — with adverse event history" can't get it from any single vendor today.
Oushvaa was built on the opposite premise. One schema. One canonical entity graph. Drugs, devices, biologics resolve to the same identifiers. Procurement workflow runs on top. Audit trails span the whole graph. The structural choice that incumbents can't reverse — that's the moat.
Oushvaa was built on a contrarian premise: the healthcare data layer can be architected, not accumulated. Most incumbents grew by acquiring single-category companies and stitching schemas together. The result is the layer cake of incompatible identifiers and lossy joins that every customer eventually runs into. We started from the canonical graph — one schema, one identity layer, three intelligence rails on top — because the structural decision is the moat. Editorial scale follows. It cannot retrofit.
The team combines deep operator experience in pharmaceutical supply chain and regulatory affairs with engineering backgrounds spanning data infrastructure and applied AI. That pairing is deliberate: pharma intelligence built by pure data engineers misses the workflow truth; platforms built by pure operators hit the architectural ceiling before they scale. Oushvaa exists at the intersection.
A senior advisory cohort across clinical practice, regulatory affairs, and pharmaceutical business development is being assembled to anchor cross-rail editorial governance. Named appointments will be published as recruitment closes.
The platform is in design-partner stage. Three intelligence rails ship live data today: DrugIQ (578K canonical drugs, India-deep), MedevIQ (19.7M FDA adverse events, 9 regulators, 64K canonical manufacturers), BiologicsIQ (111 editorial-tier biologics, 35 regulators in schema). Oushvaa Procure is in active pilot conversations with hospitals across India. Series A discussions open in mid-2027.
The next eighteen months are about depth, not breadth. DrugIQ global expansion (FDA, EMA, Health Canada drug data) closes the Indian-only positioning gap. MedevIQ frontend catches up with the data layer through device-detail pages and adverse-event monitoring. BiologicsIQ Tier-A coverage grows from 111 to 500+ products. The canonical identity graph deepens from 66K companies and 7 triple-rail entities to 100K and 50+ respectively.
Five-year vision: become the default reference layer for healthcare procurement and regulatory intelligence — drugs, devices, biologics — globally. Built audit-grade, closed by default, structurally defensible by architecture rather than by editorial accumulation alone.
Investor and partnership inquiries: hello@oushvaa.com. Customer discovery, design-partner conversations, regulatory or editorial advisory, all welcome. The fastest way to evaluate the platform is a 30-minute walkthrough.